Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday. The findings add to a growing body of evidence that the GLP-1 drugs, which also include Novo Nordisk’s Ozempic and Wegovy, have benefits beyond diabetes and weight loss.
Anu Lala, an advanced heart failure and transplant cardiologist at Mount Sinai Fuster Heart Hospital in New York City, said of patients with heart failure. “It’s improved the symptoms of heart failure. It improves the functional capacity of what these patients are now able to do. It improves their quality of life.” Lala said she is already using the medications with her own patients. “These individuals are just markedly short of breath,” said Lala, who was not involved with the research.
Nederland Laatste Nieuws, Nederland Headlines
Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.
Bron: Investingcom - 🏆 450. / 53 Lees verder »